As the leading international organization on digital therapeutic thought leadership and education, DTA is dedicated to providing patient, clinicians, payors, and policymakers with the necessary tools to evaluate and utilize DTx products. DTA’s members – including organizations dedicated to manufacturing, evaluating, supporting, and utilizing DTx products in clinical practice – work to enable expanded access to DTx products to improve clinical and health economic outcomes.
DTA is proud to advance digital therapeutics globally by:
Harmonizing DTx evaluation criteria: With the ‘DTx Value Assessment & Integration Guide’, DTA is engaging with payors, policymakers, clinicians, and other healthcare decision makers (HCDMs) to inform the development of DTx-specific evaluation criteria. The Guide provides a framework to use in assessing baseline information about DTx products, their value, and their impact in real-world settings. This first ever industry framework for the evaluation and implementation of digital therapeutics will help streamline the process of bringing safe and effective digital therapeutics into clinical use across local, regional, and national settings.
Decision makers are using this tool to assess product:
In partnership with Curebase, DTA published, “Setting the Stage for a Fit-For-Purpose DTx Evidentiary Standard”, providing a foundational set of expectations outlining the necessary clinical evidence to enable appropriate and efficient assessment reflective of the unique nature and innovation cycles of DTx products.
DTA published the ‘DTx Value Assessment & Integration Guide’– A first ever industry framework to streamline the process of bringing safe and effective digital therapeutics into clinical use.
DTA convened DTx industry leaders for an event on Capitol Hill to advocate for policy and legislation to provide better access and coverage for digital therapeutics in the US.
DTA published overviews of DTx regulatory and reimbursement pathways in eight countries as a part of our work to establish consistent and scalable frameworks for the assessment, integration, and adoption of DTx products.
DTA held a targeted feedback period to inform the development of the DTx Value Assessment & Integration Guide, a standardized evaluation framework for payors, clinicians, and manufacturers. DTA engaged with over 60+ DTx industry stakeholders through three workshops, a survey, and individual interviews.
Launched a Resource Partner Program to accelerate the development and post-launch success of clinically evaluated digital therapeutics by building a best-in-class network of commercialization and product development service providers.
DTA published one-page overviews about digital therapeutics translated into the official languages of nine countries and with specific information on regulatory and product access pathways for each resource.
Expanded DTx Product Library to launch public-facing campaign to raise awareness of DTx products on the market that are transforming global healthcare.
DTA published the report “Digital Therapeutics: Reducing Rural Health Inequalities,” that calls for Medicare and Medicaid to leverage evidence-based digital therapeutics to address critical gaps in care for underserved populations, regardless of whether disparities are based on patient age, language, culture, income, disease state, or geography.
Executed a media and public campaign to raise awareness of DTx products and their effectiveness in improving clinical and economic outcomes during and beyond Covid-19. Highlighted member company contributions.
DTA petitioned governmental bodies within countries to provide their citizens access to DTx products during and after the pandemic.
Launched a Payor Advisory Board to more intentionally engage healthcare decision makers in DTA’s work to consistently assess and demonstrate the value of digital therapeutics.
DTA collaborated with three other organizations to outline the landscape of digital health products available to end users and clinicians. This Digital Health Industry Categorization outlines how products making higher-risk medical claims must undergo greater levels of clinical evidence and regulatory oversight.
DTA member companies collaborated with fellow leaders in the healthcare industry to develop a DTx Industry Code of Ethics. This Code demonstrates DTA Member Companies’ dedication to developing and bringing DTx products to market in a responsible way.
DTA launched a Clinician Advisory Group with physicians, psychologists, nurses, and pharmacists from multiple countries to provide insight on priority projects and initiatives.
DTA staff participated in 100+ events and presentations around the world to raise awareness of DTx products and their effectiveness in improving clinical and economic outcomes.
DTA published a series of Best Practices that DTx products could utilize to demonstrate alignment with industry core principles and ensure robust product design, evaluation, and intervention delivery.
DTA launched the DTx Product Library to help key stakeholders understand and differentiate digital therapeutics from the thousands of other mobile health apps that are available. The library highlights evidence-based innovative DTx products that are currently on the market and meet the definition of a DTx product and attest to aligning with industry Core Principles.
DTA published a foundational report that provided the official industry definition of a DTx product, in addition to the ten industry core principles to which all DTx products must adhere. DTA also developed a risk-based categorization of DTx product claim types.
Through DTA’s Work Groups, DTA began to map current pathways related to product regulatory oversight and coverage within the United States and select European countries.
The Digital Therapeutics Alliance was founded as a non-profit trade association with the purpose of transforming global healthcare by advancing digital therapeutics to improve clinical and economic outcomes.